首页> 外文期刊>World Journal of Gastroenterology >Is interferon-beta an alternative treatment for chronic hepatitis C?
【24h】

Is interferon-beta an alternative treatment for chronic hepatitis C?

机译:β-干扰素是否可以替代慢性丙型肝炎?

获取原文
获取原文并翻译 | 示例
           

摘要

The treatment of chronic hepatitis C (CHC) is still far from optimal, particularly for those subpopulations that do not respond to the standard combination therapy with Interferon-alpha (IFNalpha) plus ribavirin. Although in some cases the use of higher doses or longer treatment periods may be effective, these approaches are generally associated with a higher incidence of adverse events, which may either lead to a reduction in patient compliance or require drug withdrawal. IFNbeta could represent an interesting alternative for treating CHC patients. Controversial data about IFNbeta efficacy in CHC exist, the main reason being that many results stem from pilot studies with small cohorts of patients. However, promising results have been obtained in some subgroups of patients that fail to respond to IFNalpha. Additionally, the good tolerability of IFNbeta represents an important advantage of the drug. The rates of dropouts in controlled clinical trials, as well as the need for dose reductions or treatment discontinuation are very low. It might be worth assessing the value of IFNbeta plus ribavirin in randomized studies with a larger cohort of patients, not eligible or not tolerating standard therapy, and for non-responders.
机译:慢性丙型肝炎(CHC)的治疗仍远未达到最佳效果,尤其是对于那些对干扰素-α(IFNalpha)加利巴韦林的标准联合疗法无反应的亚人群。尽管在某些情况下使用较高的剂量或更长的治疗时间可能是有效的,但这些方法通常与不良事件的发生率较高相关,这可能导致患者依从性下降或需要停药。 IFNbeta可能代表治疗CHC患者的有趣替代方法。存在关于IFNbeta在CHC中疗效的争议性数据,主要原因是许多结果来自对少量患者的初步研究。但是,在对IFNα无效的某些患者亚组中获得了可喜的结果。另外,IFNβ的良好耐受性代表了该药物的重要优点。对照临床试验中的辍学率以及降低剂量或终止治疗的需求非常低。在随机试验中,有大量患者(不符合标准或不耐受标准治疗)和无反应者,可能需要评估IFNβ加利巴韦林的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号